2022 ´ëÇѾÆÅäÇÇÇǺο°ÇÐȸ Á¦22Â÷ Çмú´ëȸ : 2022-10-02±³À°ÀÏÀÚ : 2022-10-02
±³À°Àå¼Ò : ¾Ú¹è¼´õ ¼¿ï Ç®¸¸ È£ÅÚ ±×·£µåº¼·ë 2F
±³À°ÁÖÁ¦ :
2022 ´ëÇѾÆÅäÇÇÇǺο°ÇÐȸ Á¦22Â÷ Çмú´ëȸÁÖÃÖ±â°ü : ´ëÇÑÇǺΰúÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѾÆÅäÇÇÇǺο°ÇÐȸ
´ã´çÀÚ : ÃÖ°æ¼ö
¿¬¶ôó : 02-2038-7674
À̸ÞÀÏ :
gschoi@humming.co.kr ±³À°Á¾·ù : ÇǺΰú
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 10ºÐ
¼¼ºÎ¼ö°·á : 200,000¿ø
ºñ°í Á¤È¸¿ø4¸¸¿ø,Æò»ýȸ¿ø2¸¸¿ø,Àü°øÀÇ1¸¸¿ø,ºñȸ¿ø20¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 09:30~09:40 Antipruritic effect of synthetic TRPM8 channel agonist (cryosim-1) gel on histaminergic and non-histaminergic itch in healthy human skin: a single-blind, randomized vehicle-controlled study À̼ҿ¬(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 09:40~09:50 Long-Term Efficacy of Dupilumab in South Korean Adults With Moderate-to-Severe Atopic Dermatitis: Results From an Open-Label Extension Trial ³ëÀ±Áø(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 09:50~10:00 Interferon-¥ã inducible protein 10 promotes Th2 inflammation by activating IL-4-secreting Th2 cells, exacerbating mite allergen-sensitized atopic dermatitis ¹æÁø¼±(°æºÏÀÇ´ë)
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 10:00~10:10 ASSOCIATION BETWEEN METABOLIC SYNDROME AND ATOPIC DISEASES INCLUDING ATOPIC DERMATITIS, ALLERGIC RHINITIS AND ASTHMA ±Ç¹ÎÁ¤(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 10:10~10:35 Interpretations of research data for atopic dermatitis ÀÌ¿µº¹(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 10:35~11:00 Practical laboratory tests in your clinic ÇÑÅ¿µ(À»ÁöÀÇ´ë)
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 11:00~11:20 What's new in researches of atopic dermatitis? À̵¿ÈÆ(¼¿ïÀÇ´ë)
ÈÞ½Ä 10-02 ±×·£µåº¼·ë 11:20~11:40 Break time ()
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 11:40~12:20 Recognizing the multi-dimensional impact of atopic dermatitis patients and systemic comorbidities Jonathan Silverberg(George Washington University School of Medicine and Health Sciences, USA)
½Ä»ç 10-02 ±×·£µåº¼·ë 12:20~13:10 ()
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 13:10~13:20 Mycosis fungoides Found in Patients with Atopic Dermatitis Refractory to Dupilumab ±¹Çüµ·(±¹¸³Áß¾ÓÀÇ·á¿ø)
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 13:20~13:30 New On of Alcohol Flushing in Patients with Atopic Dermatitis Treated with Dupilumab: Is It an Underrecognized Adverse Event? ½Éµ¿Çö(Á¶¼±ÀÇ´ë)
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 13:30~13:40 Preventive effects of topical diquafosol on dupilumab-associated conjunctivitis in atopic dermatitis: an open-label prospective study ÀÌÁø¼ö(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 13:40~13:50 Effects of Gamma-Linolenic Acid Adjuvant Therapy in Patients with Atopic Dermatitis: A Survey Study µµÁöÀ±(Ä«Å縯ÀÇ´ë)
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 13:50~14:30 Optimal use of Janus kinase inhibitors and dupilumab for atopic dermatitis based on the current evidence Masahiro Kamata(Teikyo University, Japan)
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 14:30~14:55 Update in pediatric atopic dermatitis Àå¿ëÇö(°æºÏÀÇ´ë)
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 14:55~15:20 Treatments of pediatric atopic dermatitis : Face to unmet needs °íÇöâ(ºÎ»êÀÇ´ë)
ÈÞ½Ä 10-02 ±×·£µåº¼·ë 15:20~15:40 Break time ()
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 15:40~16:20 Treat to target in atopic dermatitis : Significance and strategy Yoko Kataoka(Osaka Habikino Medical Center, Japan)
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 16:20~16:45 Biologics & small molecules treatment of atopic dermatitis patients : How and when? ½Å¹Î°æ(°æÈñÀÇ´ë)
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 16:45~17:10 Upcoming therapies of atopic dermatitis compared with psoriasis : What's in the pipeline? ¹èÀ¯ÀÎ(ÇѸ²ÀÇ´ë)